A new era of precision medicine is here.


With the advent of precision medicines that can target unique molecular or genetic features of a patient’s tumor, the field of oncology has a host of alternatives to one-size-fits-all treatments. This is a major advance over traditional chemotherapy, which can be as potent against healthy tissue as it is against cancer. Using tumor genomic profiling and biomarker strategies, physicians can select the patients most likely to respond well to targeted therapies. Yet, so far, due to exquisite selectivity of these new precision medicines, only relatively smaller patient populations have benefitted.

The future of precision oncology is in expanding the number of potential patients who may benefit from these innovative treatments, through a thorough understanding of cancer biology and resistance and the creation of next-generation precision medicines that seek to overcome these challenges.


Even for the patients who do benefit from precision medicine, it’s rare for cancer to be eradicated. Cancer almost always returns as tumor cells learn to adapt to the therapy and evade its effects — a phenomenon known as treatment resistance.

Through our deep understanding of cancer biology and decades of experience in precision oncology, we are revealing the underlying causes of treatment resistance. This enables us to design smart combination regimens with other cancer therapies to target tumors from multiple directions, improving the likelihood of long-term clinical benefit.


A vitally important piece of the precision medicine puzzle is our work discovering novel biomarkers — such as proteins, genes or other molecules — that indicate a patient is likely to benefit from a given treatment. Working with our clinical, laboratory and molecular pathology partners, we integrate biomarker testing into our clinical trials for patient selection and to discover novel biomarkers that may expand the number of patients who benefit from treatment. This clinical data and translational research pave the way to more efficient trials and improved patient outcomes.

At Kura, we are leading the next era of precision medicine — an era that delivers on the critical need to anticipate and circumvent common mechanisms of treatment resistance and extends the past decade of success in targeted medicines to broader patient populations.